| Symbol | QURE |
|---|---|
| Name | UNIQURE N.V. |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | PAASHEUVELWEG 25A, AMSTERDAM, 1105 BP, Netherlands |
| Telephone | +31 20 - 240-6000 |
| Fax | — |
| — | |
| Website | https://www.uniqure.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001590560 |
| Description | uniQure NV is a gene therapy company. It develops treatment and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntingtons disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Additional info from NASDAQ: |
Director Kapusta Matthew C 🟡 adjusted position in 21.1K shares (1 derivative) of uniQure N.V. (QURE) at $45.89 ($1.8M) Transaction Date: Jul 02, 2026 | Filing ID: 000397
Read moreAbi-Saab Walid 🟡 adjusted position in 30.0K shares (1 derivative) of uniQure N.V. (QURE) at $46.46 ($1.5M) Transaction Date: Jun 30, 2026 | Filing ID: 000394
Read moreDirector Kaye Jack 🟡 adjusted position in 21.2K shares (2 derivative) of uniQure N.V. (QURE) at $46.49 ($2.0M) Transaction Date: Jun 30, 2026 | Filing ID: 000392
Read more📋 Kapusta Matthew C (Officer) plans to sell 21K shares of uniQure N.V. (at $45.15 each, total $952K) Filed: Jul 02, 2026 | ID: 000264
Read moreAbi-Saab Walid 🔴 sold 1.4K shares of uniQure N.V. (QURE) at $46.86 Transaction Date: Jun 26, 2026 | Filing ID: 000387
Read moreDirector Kapusta Matthew C 🟡 adjusted position in 35.4K shares (2 derivative) of uniQure N.V. (QURE) at $50.02 ($3.9M) Transaction Date: Jun 24, 2026 | Filing ID: 000375
Read moreuniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
Read more📋 Kapusta Matthew C (Officer) plans to sell 29K shares of uniQure N.V. (at $50.02 each, total $1.4M) Filed: Jun 25, 2026 | ID: 000254
Read more📋 Kapusta Matthew C (Officer) plans to sell 7K shares of uniQure N.V. (at $50.00 each, total $335K) Filed: Jun 24, 2026 | ID: 000252
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06100276 | Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administe… | Phase1 | Amyotrophic Lateral Sclerosis | Active_Not_Recruiting | 2024-08-01 | 2031-06-30 | ClinicalTrials.gov |
| NCT06063850 | AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal… | Phase1 | Mesial Temporal Lobe Epilepsy | Recruiting | 2024-06-12 | 2031-12-01 | ClinicalTrials.gov |
| NCT06270316 | Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disea… | Phase1 | Fabry Disease | Recruiting | 2024-06-05 | 2031-04-30 | ClinicalTrials.gov |
| NCT05243017 | Safety and Efficacy of AMT-130 in European Adults With Early Manifest Huntingto… | Phase1 | Huntington Disease | Active_Not_Recruiting | 2021-10-07 | 2029-10-07 | ClinicalTrials.gov |
| NCT04723680 | An Exploration of the Impact of Gene Therapy on the Lives of People With Haemop… | — | Hemophilia | Completed | 2020-08-13 | 2023-02-28 | ClinicalTrials.gov |
| NCT04120493 | Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manif… | Phase1 | Huntington's Disease | Active_Not_Recruiting | 2019-09-06 | 2029-12-01 | ClinicalTrials.gov |
| NCT02904772 | Alipogene Tiparvovec for the Treatment of LPLD Patients | Phase2 | LPL Deficiency | Withdrawn | 2016-10-01 | 2020-09-01 | ClinicalTrials.gov |
| NCT03293810 | Glybera Registry, Lipoprotein Lipase Deficient (LPLD) Patients | — | Lipoprotein Lipase Deficiency | Completed | 2014-06-27 | 2023-06-01 | ClinicalTrials.gov |
| NCT03300453 | Intracerebral Gene Therapy in Children With Sanfilippo Type B Syndrome | Phase1 | Sanfilippo Syndrome B | Completed | 2013-09-17 | 2019-11-27 | ClinicalTrials.gov |
| NCT02082860 | Phase I Gene Therapy Clinical Trial Using the Vector rAAV2/5-PBGD for the Treat… | Phase1 | Acute Intermittent Porphyria | Completed | 2012-11-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT02076763 | Observational Study of Acute Intermittent Porphyria Patients | — | Acute Intermittent Porphyria | Completed | 2011-08-01 | 2014-02-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| AAV9-hSyn1-miGRIK2 | Other | Phase PHASE1 | Mesial Temporal Lobe Epilepsy | RECRUITING | NCT06063850 |
| rAAV2/5-PBGD vector dosage 4 | Other | Phase PHASE1 | Acute Intermittent Porphyria | COMPLETED | NCT02082860 |
| rAAV2/5-PBGD vector dosage 3 | Other | Phase PHASE1 | Acute Intermittent Porphyria | COMPLETED | NCT02082860 |
| rAAV2/5-PBGD vector dosage 2 | Other | Phase PHASE1 | Acute Intermittent Porphyria | COMPLETED | NCT02082860 |
| rAAV2/5-PBGD vector dosage 1 | Other | Phase PHASE1 | Acute Intermittent Porphyria | COMPLETED | NCT02082860 |
| Mycophenolate mofetil | Other | Phase PHASE2 | LPL Deficiency | WITHDRAWN | NCT02904772 |
| Cyclosporins | Other | Phase PHASE2 | LPL Deficiency | WITHDRAWN | NCT02904772 |
| Prednisolone | Other | Phase PHASE2 | LPL Deficiency | WITHDRAWN | NCT02904772 |
| alipogene tiparvovec | Other | Phase PHASE2 | LPL Deficiency | WITHDRAWN | NCT02904772 |
| rAAV2/5-hNAGLU | Other | Phase PHASE1 | Sanfilippo Syndrome B | COMPLETED | NCT03300453 |
| Qualitative interview | Other | Preclinical | Hemophilia | COMPLETED | NCT04723680 |
| Qualitative interview | Other | Preclinical | Hemophilia | COMPLETED | NCT04723680 |
| Observational study | Other | Preclinical | Lipoprotein Lipase Deficiency | COMPLETED | NCT03293810 |
| Observational study | Other | Preclinical | Lipoprotein Lipase Deficiency | COMPLETED | NCT03293810 |
| intra-striatal rAAV5-miHTT | Other | Phase PHASE1 | Huntington Disease | ACTIVE_NOT_RECRUITING | NCT05243017 |
| intra-striatal rAAV5-miHTT | Other | Phase PHASE1 | Huntington Disease | ACTIVE_NOT_RECRUITING | NCT05243017 |
| AAV9-hSyn1-miGRIK2 | Other | Phase PHASE1 | Mesial Temporal Lobe Epilepsy | RECRUITING | NCT06063850 |
| AAV9-hSyn1-miGRIK2 | Other | Phase PHASE1 | Mesial Temporal Lobe Epilepsy | RECRUITING | NCT06063850 |
| Imitation (sham) surgery | Procedure | Phase PHASE1 | Huntington's Disease | ACTIVE_NOT_RECRUITING | NCT04120493 |
| intra-striatal rAAV5-miHTT | Other | Phase PHASE1 | Huntington's Disease | ACTIVE_NOT_RECRUITING | NCT04120493 |
| Imitation (sham) surgery | Procedure | Phase PHASE1 | Huntington's Disease | ACTIVE_NOT_RECRUITING | NCT04120493 |
| intra-striatal rAAV5-miHTT | Other | Phase PHASE1 | Huntington's Disease | ACTIVE_NOT_RECRUITING | NCT04120493 |
| AMT-162 | Other | Phase PHASE1 | Amyotrophic Lateral Sclerosis | ACTIVE_NOT_RECRUITING | NCT06100276 |
| AMT-162 | Other | Phase PHASE1 | Amyotrophic Lateral Sclerosis | ACTIVE_NOT_RECRUITING | NCT06100276 |
| AMT-191 | Other | Phase PHASE1 | Fabry Disease | RECRUITING | NCT06270316 |
| AMT-191 | Other | Phase PHASE1 | Fabry Disease | RECRUITING | NCT06270316 |
| rAAV2/5-hNAGLU | DRUG | Phase PHASE1 | Sanfilippo Syndrome B | COMPLETED | NCT03300453 |
| Mycophenolate mofetil | DRUG | Phase PHASE2 | LPL Deficiency | WITHDRAWN | NCT02904772 |
| Cyclosporins | DRUG | Phase PHASE2 | LPL Deficiency | WITHDRAWN | NCT02904772 |
| Prednisolone | DRUG | Phase PHASE2 | LPL Deficiency | WITHDRAWN | NCT02904772 |
| alipogene tiparvovec | DRUG | Phase PHASE2 | LPL Deficiency | WITHDRAWN | NCT02904772 |
| rAAV2/5-PBGD vector dosage 4 | GENETIC | Phase PHASE1 | Acute Intermittent Porphyria | COMPLETED | NCT02082860 |
| rAAV2/5-PBGD vector dosage 3 | GENETIC | Phase PHASE1 | Acute Intermittent Porphyria | COMPLETED | NCT02082860 |
| rAAV2/5-PBGD vector dosage 2 | GENETIC | Phase PHASE1 | Acute Intermittent Porphyria | COMPLETED | NCT02082860 |
| rAAV2/5-PBGD vector dosage 1 | GENETIC | Phase PHASE1 | Acute Intermittent Porphyria | COMPLETED | NCT02082860 |